Hommels, T. M.
Hermanides, R. S.
Rasoul, S.
Berta, B.
IJsselmuiden, A. J. J.
Jessurun, G. A. J.
Benit, E.
Pereira, B.
De Luca, G.
Kedhi, E.
Funding for this research was provided by:
Maatschap Cardiologie Isala Hartcentrum, Isala Klinieken, Zwolle
Article History
First Online: 13 June 2019
Conflict of interest
: T.M. Hommels, R.S. Hermanides, S. Rasoul, B. Berta, A.J.J. IJsselmuiden, G.A.J. Jessurun, E. Benit, B. Pereira, G. De Luca and E. Kedhi declare that they have no competing interests.
: The prospective study was performed in accordance with the Declaration of Helsinki (DoH) and was registered in the Netherlands Trial Register (NTR) acknowledged by the World Health Organisation (WHO) and International Committee of Medical Journal Editors (ICMJE). Approval for ethical committees was sought in all participating centres and countries. This clinical investigation did not test any new device. The ABSORB BVS and the ABSORB GT1 are CE marked products and were used widely in daily clinical practice all over the world from 2009 to 2017. This clinical register does not involve a medicinal product and is therefore not subject to The European Clinical Trials Directive (2001/20/EC).